Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor
出版年份 2013 全文链接
标题
Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor
作者
关键词
-
出版物
HISTOPATHOLOGY
Volume 63, Issue 2, Pages 225-233
出版商
Wiley
发表日期
2013-04-01
DOI
10.1111/his.12156
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Emerging new roles of Th17 cells
- (2012) Vijay K. Kuchroo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Life, death, and miracles: Th17 cells in the intestine
- (2012) Samuel Huber et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Small molecule inhibitors of RORγt: Targeting Th17 cells and other applications
- (2012) Jun R. Huh et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β
- (2012) Christina E. Zielinski et al. NATURE
- Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer
- (2011) Rulla M. Tamimi et al. BREAST CANCER RESEARCH AND TREATMENT
- Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?
- (2011) Elisabeth Ersvær et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer
- (2011) Marie Tosolini et al. CANCER RESEARCH
- Microbial Dysbiosis in Colorectal Cancer (CRC) Patients
- (2011) Iradj Sobhani et al. PLoS One
- Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules
- (2010) Andrew E Teschendorff et al. BMC CANCER
- An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer
- (2010) Sahar M. A. Mahmoud et al. BREAST CANCER RESEARCH AND TREATMENT
- Signal transduction pathways and transcriptional regulation in Th17 cell differentiation
- (2010) Kiyoshi Hirahara et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Generation of pathogenic TH17 cells in the absence of TGF-β signalling
- (2010) Kamran Ghoreschi et al. NATURE
- Human ROR t+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors
- (2010) D. Valmori et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. Journal of Oncology Practice
- IL-17 and Th17 Cells
- (2009) Thomas Korn et al. Annual Review of Immunology
- Endogenous IL-17 contributes to reduced tumor growth and metastasis
- (2009) I. Kryczek et al. BLOOD
- The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer
- (2009) C Horlock et al. BRITISH JOURNAL OF CANCER
- Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
- (2009) Marcin Kortylewski et al. CANCER CELL
- IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
- (2009) Lin Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses
- (2009) Shaoguang Wu et al. NATURE MEDICINE
- Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells
- (2008) Franca Gerosa et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Human interleukin 17–producing cells originate from a CD161+CD4+T cell precursor
- (2008) Lorenzo Cosmi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- IL-21 and TGF-β are required for differentiation of human TH17 cells
- (2008) Li Yang et al. NATURE
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started